NCT04549428View on ClinicalTrials.gov

Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 1, 2020

Primary Completion Date

January 23, 2023

Study Completion Date

December 31, 2024

Conditions
NSCLC Stage IV
Interventions
DRUG

Atezolizumab

Intravenous infusion every 21 days, until disease progression, intolerance or loss of clinical benefit.

Trial Locations (3)

1205

Geneva University Hospitals (HUG), Geneva

6500

Oncology Institute of Southern Switzerland, Bellinzona

7000

Cantonal Hospital of Graubünden (KSGR), Chur

All Listed Sponsors
collaborator

Ente Ospedaliero Cantonale, Bellinzona

OTHER

collaborator

Istituto Cantonale di Patologia

OTHER

collaborator

Clinical Trial Unit Ente Ospedaliero Cantonale

OTHER

lead

Oncology Institute of Southern Switzerland

OTHER